NxStage Medical, Inc. (NASDAQ:NXTM) SVP Winifred L. Swan sold 3,500 shares of the business’s stock in a transaction dated Friday, October 20th. The stock was sold at an average price of $27.50, for a total transaction of $96,250.00. Following the completion of the transaction, the senior vice president now directly owns 15,270 shares of the company’s stock, valued at $419,925. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

NxStage Medical, Inc. (NASDAQ:NXTM) traded down 0.47% during midday trading on Monday, hitting $27.38. 330,876 shares of the company were exchanged. The firm’s 50-day moving average price is $27.66 and its 200-day moving average price is $25.91. The stock’s market capitalization is $1.81 billion. NxStage Medical, Inc. has a one year low of $20.45 and a one year high of $30.80.

NxStage Medical (NASDAQ:NXTM) last posted its earnings results on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The business had revenue of $92.20 million for the quarter, compared to the consensus estimate of $96.47 million. During the same period last year, the company earned ($0.03) EPS. The firm’s revenue was up .0% compared to the same quarter last year. Equities research analysts anticipate that NxStage Medical, Inc. will post ($0.05) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/10/23/nxstage-medical-inc-nxtm-svp-sells-96250-00-in-stock.html.

Large investors have recently bought and sold shares of the stock. CWM LLC acquired a new stake in NxStage Medical during the 2nd quarter worth approximately $2,684,000. Birchview Capital LP boosted its position in NxStage Medical by 21.3% during the 2nd quarter. Birchview Capital LP now owns 34,200 shares of the medical device company’s stock worth $857,000 after buying an additional 6,000 shares during the period. Russell Investments Group Ltd. boosted its position in NxStage Medical by 67.9% during the 1st quarter. Russell Investments Group Ltd. now owns 28,847 shares of the medical device company’s stock worth $773,000 after buying an additional 11,668 shares during the period. Redmile Group LLC acquired a new stake in NxStage Medical during the 2nd quarter worth approximately $16,480,000. Finally, Schwab Charles Investment Management Inc. boosted its position in NxStage Medical by 7.0% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 277,899 shares of the medical device company’s stock worth $7,457,000 after buying an additional 18,189 shares during the period. Institutional investors and hedge funds own 92.66% of the company’s stock.

A number of brokerages have weighed in on NXTM. Zacks Investment Research raised shares of NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a research note on Thursday, August 10th. Craig Hallum began coverage on shares of NxStage Medical in a research note on Tuesday, June 27th. They issued a “buy” rating and a $32.00 target price for the company. BTIG Research downgraded shares of NxStage Medical from a “buy” rating to a “neutral” rating in a research note on Friday, August 11th. Canaccord Genuity downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 target price for the company. in a research note on Monday, August 7th. Finally, BidaskClub downgraded shares of NxStage Medical from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Two analysts have rated the stock with a sell rating and eight have given a hold rating to the company. The stock presently has an average rating of “Hold” and an average price target of $30.25.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Insider Buying and Selling by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.